STAT3-Mediated Promoter-Enhancer Interaction Up-Regulates Inhibitor of DNA Binding 1 () to Promote Colon Cancer Progression

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Jun 28

PMID 37373188

Authors

Zhike Lin

Ying Liu

Tian Xu

Ting Su

Yingying Yang

Runhua Liang

Songgang Gu

Jie Li

Xuhong Song

Bin Liang

Zhijun Leng

Yangsihan Li

Lele Meng

Yijing Luo

Xiaolan Chang

Dongyang Huang

Lingzhu Xie

Affiliations

Soon will be listed here.

Abstract

Background: High expression of inhibitor of DNA binding 1 () correlates with poor prognosis in colorectal cancer (CRC). Aberrant enhancer activation in regulating transcription is limited.

Methods: Immunohistochemistry (IHC), quantitative RT-PCR (RT-qPCR) and Western blotting (WB) were used to determine the expression of . CRISPR-Cas9 was used to generate or enhancer E1 knockout cell lines. Dual-luciferase reporter assay, chromosome conformation capture assay and ChIP-qPCR were used to determine the active enhancers of . Cell Counting Kit 8, colony-forming, transwell assays and tumorigenicity in nude mice were used to investigate the biological functions of and enhancer E1.

Results: Human CRC tissues and cell lines expressed a higher level of than normal controls. promoted CRC cell proliferation and colony formation. Enhancer E1 actively regulated promoter activity. Signal transducer and activator of transcription 3 (STAT3) bound to promoter and enhancer E1 to regulate their activity. The inhibitor of STAT3 Stattic attenuated promoter and enhancer E1 activity and the expression of . Enhancer E1 knockout down-regulated expression level and cell proliferation in vitro and in vivo.

Conclusions: Enhancer E1 is positively regulated by STAT3 and contributes to the regulation of to promote CRC cell progression and might be a potential target for anti-CRC drug studies.

References

Huang Y, Hu J, Chen F, Lecomte N, Basnet H, David C . ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer. Cancer Discov. 2019; 10(1):142-157. PMC: 6954299. DOI: 10.1158/2159-8290.CD-19-0529. View

Kang S, Tanaka T, Narazaki M, Kishimoto T . Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019; 50(4):1007-1023. DOI: 10.1016/j.immuni.2019.03.026. View

Lai X, Liao J, Lin W, Huang C, Li J, Lin J . Inhibitor of DNA-binding protein 1 knockdown arrests the growth of colorectal cancer cells and suppresses hepatic metastasis in vivo. Oncol Rep. 2014; 32(1):79-88. DOI: 10.3892/or.2014.3172. View

Zhao Y, Zhu J, Shi B, Wang X, Lu Q, Li C . The transcription factor LEF1 promotes tumorigenicity and activates the TGF-β signaling pathway in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2019; 38(1):304. PMC: 6625065. DOI: 10.1186/s13046-019-1296-7. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Yu M, Ren B . The Three-Dimensional Organization of Mammalian Genomes. Annu Rev Cell Dev Biol. 2017; 33:265-289. PMC: 5837811. DOI: 10.1146/annurev-cellbio-100616-060531. View

Ye R, Cao C, Xue Y . Enhancer RNA: biogenesis, function, and regulation. Essays Biochem. 2020; 64(6):883-894. DOI: 10.1042/EBC20200014. View

Lee T, Young R . Transcriptional regulation and its misregulation in disease. Cell. 2013; 152(6):1237-51. PMC: 3640494. DOI: 10.1016/j.cell.2013.02.014. View

Liu Q, Zhang C, Yuan J, Fu J, Wu M, Su J . PTK7 regulates Id1 expression in CD44-high glioma cells. Neuro Oncol. 2014; 17(4):505-15. PMC: 4483067. DOI: 10.1093/neuonc/nou227. View

10.

Goldstein I, Paakinaho V, Baek S, Sung M, Hager G . Synergistic gene expression during the acute phase response is characterized by transcription factor assisted loading. Nat Commun. 2017; 8(1):1849. PMC: 5707366. DOI: 10.1038/s41467-017-02055-5. View

11.

Sanjana N, Shalem O, Zhang F . Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014; 11(8):783-784. PMC: 4486245. DOI: 10.1038/nmeth.3047. View

12.

Sur I, Taipale J . The role of enhancers in cancer. Nat Rev Cancer. 2016; 16(8):483-93. DOI: 10.1038/nrc.2016.62. View

13.

Oksuz B, Yang L, Abraham S, Venev S, Krietenstein N, Parsi K . Systematic evaluation of chromosome conformation capture assays. Nat Methods. 2021; 18(9):1046-1055. PMC: 8446342. DOI: 10.1038/s41592-021-01248-7. View

14.

Galbraith M, Allen M, Bensard C, Wang X, Schwinn M, Qin B . HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell. 2013; 153(6):1327-39. PMC: 3681429. DOI: 10.1016/j.cell.2013.04.048. View

15.

Lv D, Li Y, Zhang W, Alvarez A, Song L, Tang J . TRIM24 is an oncogenic transcriptional co-activator of STAT3 in glioblastoma. Nat Commun. 2017; 8(1):1454. PMC: 5682287. DOI: 10.1038/s41467-017-01731-w. View

16.

Andersson R, Sandelin A . Determinants of enhancer and promoter activities of regulatory elements. Nat Rev Genet. 2019; 21(2):71-87. DOI: 10.1038/s41576-019-0173-8. View

17.

Tian J, Chang J, Gong J, Lou J, Fu M, Li J . Systematic Functional Interrogation of Genes in GWAS Loci Identified ATF1 as a Key Driver in Colorectal Cancer Modulated by a Promoter-Enhancer Interaction. Am J Hum Genet. 2019; 105(1):29-47. PMC: 6612518. DOI: 10.1016/j.ajhg.2019.05.004. View

18.

Li Q, Su Z, Xu X, Liu G, Song X, Wang R . AS1DHRS4, a head-to-head natural antisense transcript, silences the DHRS4 gene cluster in cis and trans. Proc Natl Acad Sci U S A. 2012; 109(35):14110-5. PMC: 3435198. DOI: 10.1073/pnas.1116597109. View

19.

He Y, Wei T, Ye Z, Orme J, Lin D, Sheng H . A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nat Commun. 2021; 12(1):1521. PMC: 7943793. DOI: 10.1038/s41467-021-21860-7. View

20.

Krijger P, Geeven G, Bianchi V, Hilvering C, de Laat W . 4C-seq from beginning to end: A detailed protocol for sample preparation and data analysis. Methods. 2019; 170:17-32. DOI: 10.1016/j.ymeth.2019.07.014. View